Atrium Therapeutics, Inc.
RNA
$12.69
$0.373.00%
NASDAQ
| 12/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Net Income | -29.14M | -11.51M | |||
| Total Depreciation and Amortization | 122.00K | 58.00K | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 4.00M | 6.42M | |||
| Change in Net Operating Assets | 5.76M | -3.23M | |||
| Cash from Operations | -19.25M | -8.26M | |||
| Capital Expenditure | -879.00K | -218.00K | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -879.00K | -218.00K | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 20.13M | 8.48M | |||
| Cash from Financing | 20.13M | 8.48M | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -- | -- | |||